MapLight Therapeutics, Inc. (MPLT)
| Market Cap | 702.86M |
| Revenue (ttm) | n/a |
| Net Income | -199.48M |
| EPS | -10.07 |
| Shares Out | 45.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,143,121 |
| Open | 12.63 |
| Previous Close | 12.31 |
| Day's Range | 12.56 - 15.29 |
| 52-Week Range | 9.10 - 40.43 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 32.31 (+108.45%) |
| Earnings Date | Aug 28, 2026 |
About MPLT
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company’s products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer’s disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson’s disease; ML-055 for the treatment of neuropsychiatric co... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for MPLT stock is "Strong Buy." The 12-month stock price target is $32.31, which is an increase of 108.45% from the latest price.
News
MapLight Therapeutics price target lowered to $25 from $40 at Craig-Hallum
Craig-Hallum analyst Adam Vogel lowered the firm’s price target on MapLight Therapeutics (MPLT) to $25 from $40 and keeps a Buy rating on the shares. The firm notes ML-007 positive…
MapLight Therapeutics price target lowered to $24 from $43 at Canaccord
Canaccord lowered the firm’s price target on MapLight Therapeutics (MPLT) to $24 from $43 and keeps a Buy rating on the shares. The firm updated its model following the company’s…
MapLight downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley downgraded MapLight Therapeutics (MPLT) to Equal Weight from Overweight with a price target of $21, down from $34. While the ZEPHYR study shows ML-007 is pharmacologically active in…
MapLight Therapeutics price target lowered to $26 from $45 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on MapLight Therapeutics (MPLT) to $26 from $45 and keeps a Buy rating on the shares after the company reported…
MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $MPLT--MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law.
MapLight's schizophrenia drug fails once-daily test, shares plunge
MapLight Therapeutics said on Monday its schizophrenia drug failed to show statistically significant symptom improvement in the once-daily dosing arm of a mid-stage trial, sending its shares tumbling...
MapLight Therapeutics Transcript: Study result
The phase II ZEPHYR study of ML-007C-MA in schizophrenia met its primary endpoint, showing significant efficacy on PANSS and cognitive measures, with a favorable safety and tolerability profile. The cognitive benefit appears independent of antipsychotic effects, supporting further pivotal studies and expansion into Alzheimer's disease psychosis.
MapLight Therapeutics Slides: Study result
MapLight Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 27, 2026.
MapLight Therapeutics Press release: Study result
MapLight Therapeutics issued a press release on July 27, 2026, disclosing material business information to investors.
MapLight Therapeutics announces topline results from ZEPHYR trial
MapLight Therapeutics (MPLT) announced topline results from its Phase 2 ZEPHYR trial evaluating ML-007C-MA, an oral M1/M4 muscarinic agonist co-formulated with a peripherally acting anticholinergic, i...
MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia
The trial, designed and sized to support registration, met its primary endpoint, with the 210/3 mg BID dose demonstrating a statistically significant improvement in PANSS total score compared to place...
MapLight Therapeutics price target raised to $43 from $35 at Canaccord
Canaccord analyst Sumant Kulkarni raised the firm’s price target on MapLight Therapeutics (MPLT) to $43 from $35 and keeps a Buy rating on the shares. The firm said the company…
MapLight Therapeutics price target raised to $52 from $48 at UBS
UBS raised the firm’s price target on MapLight Therapeutics (MPLT) to $52 from $48 and keeps a Buy rating on the shares. The upcoming Phase 2 readout for ML-007 in…
BMO starts MapLight at Outperform, eyes validation data in August
BMO Capital initiated coverage of MapLight Therapeutics (MPLT) with an Outperform rating and $46 price target MapLight’s dual muscarinic agonist ML-007C-MA looks to demonstrate improved tolerability w...
MapLight Therapeutics initiated with an Outperform at BMO Capital
BMO Capital initiated coverage of MapLight Therapeutics (MPLT) with an Outperform rating and $46 price target
MapLight Therapeutics price target raised to $45 from $42 at Needham
Needham analyst Ami Fada raised the firm’s price target on MapLight Therapeutics (MPLT) to $45 from $42 and keeps a Buy rating on the shares. Following its management meetings, the…
MapLight Therapeutics initiated with a Strong Buy at Raymond James
Raymond James initiated coverage of MapLight Therapeutics (MPLT) with a Strong Buy rating and $46 price target Cobenfy marks the first major mechanistic innovation in schizophrenia treatment in over t...
MapLight Therapeutics Announces Changes to Board of Directors
SAN FRANCISCO and BOSTON, June 24, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering ...
MapLight Therapeutics price target lowered to $40 from $43 at Craig-Hallum
Craig-Hallum lowered the firm’s price target on MapLight Therapeutics (MPLT) to $40 from $43 and keeps a Buy rating on the shares. MapLight’s ML-004 Phase 2 IRIS results were mixed…
MapLight Therapeutics Transcript: Study result
ML-004 did not improve social communication in ASD but showed robust, clinically meaningful reductions in irritability among adolescents with moderate to severe symptoms, with effect sizes exceeding current therapies and a favorable safety profile. It was well-tolerated, with no severe adverse events and minimal weight gain or sedation.
MapLight Therapeutics Press release: Study result
MapLight Therapeutics issued a press release on June 22, 2026, disclosing material business information to investors.
MapLight Therapeutics Slides: Study result
MapLight Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 22, 2026.
MapLight Therapeutics announces IRIS trial misses primary endpoint
MapLight Therapeutics (MPLT) announced topline results from IRIS, a Phase 2 study of ML-004 in autism spectrum disorder, or ASD. The study randomized 161 participants with prespecified analyses planne...
MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder
SAN FRANCISCO and BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering ...
MapLight Therapeutics price target raised to $36 from $28 at Stifel
Stifel raised the firm’s price target on MapLight Therapeutics (MPLT) to $36 from $28 and keeps a Buy rating on the shares following the firm’s recent meetings with CEO Chris…